TheProfitWatch

MNPR - Monopar Therapeutics Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
82.54 11.91 (14.43%) --- --- 3.48 (3.82%) --- 11.91 (14.43%) --- ---

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.35
Diluted EPS:
Basic P/E:
-269.8571
Diluted P/E:
RSI(14) 1m:
60.7
VWAP:
94.39
RVol:

Events

Period Kind Movement Occurred At

Related News